ONCONOVA THERAPEUTICS INC (ONTX) Stock News

NASDAQ:ONTX - Nasdaq - US68232V8019 - Common Stock - Currency: USD

0.9953 0 (-0.47%)

After market: 0.9012 -0.09 (-9.45%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ONTX Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: The Motley Fool - Mentions: TRAW

Traws Pharma Posts Q2 Revenue Jump

a year ago - By: Onconova Therapeutics, Inc.

Traws Pharma Announces New Employee Inducement Grants

a year ago - By: Onconova Therapeutics, Inc.

Traws Pharma Announces New Employee Inducement Grants

a year ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

a year ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

2 years ago - By: Benzinga

Onconova Therapeutics's Earnings: A Preview

a year ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024

1 years ago - By: Benzinga - Mentions: CPHI PACB ONMD SNES ...

12 Health Care Stocks Moving In Thursday's After-Market Session

2 years ago - By: Seeking Alpha

Onconova stock falls 10% on preclinical data for lymphoma drug (NASDAQ:ONTX)

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma

2 years ago - By: InvestorPlace - Mentions: JTAI NXTP VIRC PSTX ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Expands Leadership Team with Two Key Appointments

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Expands Leadership Team with Two Key Appointments

2 years ago - By: Onconova Therapeutics, Inc.

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

2 years ago - By: Onconova Therapeutics, Inc.

Promising Preclinical Narazaciclib Data Presented at MCL Meeting

2 years ago - By: Onconova Therapeutics, Inc.

Encouraging Rigosertib Data Presented at EADV as Late Breaker

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

2 years ago - By: Onconova Therapeutics, Inc.

Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results